Evidence map›Paper›PMID 40590246›Full record

ArticleHistopathology2025

Renal cell carcinoma with fibromyomatous stroma (RCC FMS) and with hemangioblastoma-like areas is part of the RCC FMS spectrum in patients with tuberous sclerosis complex.

Katherina Baranova, Jacob A Houpt, Deaglan Arnold, Andrew A House, Laura Lockau, Lindsay Ninivirta, Stephen Pautler, Haiying Chen, Madeleine Moussa, Rola Saleeb and 8 more

Abstract read
In one paragraph

Article in Histopathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Hemangioblastoma of the Kidney-A Comprehensive Clinical, Pathological, and Genetic Analysis of Four Cases.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2026
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Katherina BaranovaDepartment of Pathology and Laboratory Medicine, London Health Sciences Centre, London, ON, Canada.ORCID https://orcid.org/0000-0003-4740-9789
Jacob A HouptDepartment of Pathology and Laboratory Medicine, London Health Sciences Centre, London, ON, Canada.ORCID https://orcid.org/0000-0002-7505-0681
Deaglan ArnoldSchulich School of Medicine and Dentistry, London Health Sciences Centre, London, ON, Canada.
Andrew A HouseDepartment of Medicine, Western University and London Health Sciences Centre, London, ON, Canada.ORCID https://orcid.org/0000-0001-7152-6163
Laura LockauDepartment of Pathology and Laboratory Medicine, London Health Sciences Centre, London, ON, Canada.
Lindsay NinivirtaDepartment of Pathology and Laboratory Medicine, London Health Sciences Centre, London, ON, Canada.
Stephen PautlerDivisions of Urology and Surgical Oncology, Departments of Surgery and Oncology, Western University, London, ON, Canada.ORCID https://orcid.org/0000-0001-9281-8122
Haiying ChenDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
Madeleine MoussaDepartment of Pathology and Laboratory Medicine, London Health Sciences Centre, London, ON, Canada.ORCID https://orcid.org/0000-0003-4786-6226
Rola SaleebDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.ORCID https://orcid.org/0000-0002-1937-3101
Jose A GomezDepartment of Pathology and Laboratory Medicine, London Health Sciences Centre, London, ON, Canada.
Asli YilmazDiagnostic and Molecular Pathology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Farshid SiadatDiagnostic and Molecular Pathology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.ORCID https://orcid.org/0000-0001-7676-4806
Adrian BoxDiagnostic and Molecular Pathology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Douglas J MahoneyDepartment of Biochemistry and Molecular Biology, Arnie Charbonneau Cancer Institute, Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Franz J ZempDepartment of Biochemistry and Molecular Biology, Arnie Charbonneau Cancer Institute, Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Manal GabrilDepartment of Pathology and Laboratory Medicine, London Health Sciences Centre, London, ON, Canada.
Kiril TrpkovDiagnostic and Molecular Pathology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.ORCID https://orcid.org/0000-0003-3142-8846

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsSporadic renal cell carcinomas with fibromyomatous stroma (RCC FMS) with coexistent haemangioblastoma (HB)-like morphology have been previously reported. Such morphology has not, however, been documented in patients with tuberous sclerosis complex (TSC). We evaluated clinicopathologic, immunohistochemical and molecular findings of RCC FMS with HB-like features in three TSC patients. METHODS AND

resultsAll three patients were females with confirmed germline mutations in TSC1 in the absence of VHL or other alterations. One patient had bilateral nephrectomy with six separate tumours (three in each kidney), and two patients had one tumour each, resected by partial nephrectomy. Prominent fibromuscular stroma was present at the tumoral periphery and surrounding clear cell nests forming tubules and papillary formations (RCC FMS areas), admixed with solid, clear to eosinophilic and spindle cell areas (HB-like areas). HB-like areas were variably represented in individual tumours, but in some, HB-like features were almost exclusive. HB-like areas were negative for CK7 and showed inhibin-α and S100 reactivity, in contrast to typical RCC FMS areas, which were CK7 positive, while negative for inhibin-α and S100. GPNMB, which is consistently expressed in TSC/mTOR altered tumours, was positive in both components. On follow-up (10 months-21 years), all patients had an indolent course.

conclusionsHB-like morphology found in RCC FMS in TSC patients represents part of the morphologic spectrum of RCC FMS, which is a previously underreported and underrecognized feature. RCC FMS with HB-like areas show uniform GPNMB reactivity and are associated with TSC/MTOR alterations, but not with VHL alterations.

Indexed as

Carcinoma, Renal CellHemangioblastomaKidney NeoplasmsTuberous SclerosisAdultBiomarkers, TumorFemaleHumansMiddle AgedTuberous Sclerosis Complex 1 ProteinBiomarkers, TumorTSC1 protein, humanTuberous Sclerosis Complex 1 Proteinclear cellfibromyomatous stromahaemagioblastomakidneyleiomyomatous stromarenal cell carcinoma (RCC)TSC

Identifiers

PMID40590246
PMCPMC12522018

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.